Literature DB >> 19632931

Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin.

Ubaidullah Sharief1, David J Perry.   

Abstract

Reversible posterior leukoencephalopathy (RPLS), also known as posterior reversible encephalopathy syndrome, is characterized by magnetic resonance imaging (MRI) findings of reversible vasogenic subcortical edema without infarction. The clinical presentation is usually nonspecific and typically involves global encephalopathy, seizures, headache, or visual symptoms. MRI of the brain is essential to the diagnosis of RPLS. Typical findings of RPLS include high-intensity signal on T2-weighted images predominantly in the posterior lobes of the brain that is caused by subcortical white matter vasogenic edema. Fluid-attenuated inversion recovery (FLAIR) sequences on MRI improve sensitivity and detect subtle peripheral lesions. This clinical radiographic syndrome has been described in a number of medical conditions, with hypertensive encephalopathy, eclampsia, and the use of immunosuppressant drugs (most notably calcineurin inhibitors) being the most common. It has occasionally been reported with cisplatin and rarely with carboplatin. Its occurrence with oxaliplatin is very unusual. An extensive literature search including PUBMED and direct contact with the drug manufacturer yielded only 2 known case reports. Herein, we describe a case that had classic clinical and radiologic features of RPLS. We also briefly describe 2 other patients who have been described to have RPLS with oxaliplatin in the literature.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19632931     DOI: 10.3816/CCC.2009.n.026

Source DB:  PubMed          Journal:  Clin Colorectal Cancer        ISSN: 1533-0028            Impact factor:   4.481


  12 in total

1.  Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study.

Authors:  Carlos Kamiya-Matsuoka; Asif M Paker; Linda Chi; Ayda Youssef; Sudhakar Tummala; Monica E Loghin
Journal:  J Neurooncol       Date:  2016-02-22       Impact factor: 4.130

2.  Primary brain tumors and posterior reversible encephalopathy syndrome.

Authors:  Carlos Kamiya-Matsuoka; David Cachia; Adriana Olar; Terri S Armstrong; Mark R Gilbert
Journal:  Neurooncol Pract       Date:  2014-09-14

Review 3.  Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome: A Case Report and Review of the Literature.

Authors:  Joan How; Margaret Blattner; Susan Fowler; Andrea Wang-Gillam; Suzanne E Schindler
Journal:  Neurologist       Date:  2016-11       Impact factor: 1.398

4.  Unexpected seizure attack in a patient with spinal metastasis diagnosed as posterior reversible encephalopathy syndrome.

Authors:  Chang Hyoun Kim; Chi Heon Kim; Chun Kee Chung; Tae-Ahn Jahng
Journal:  J Korean Neurosurg Soc       Date:  2011-07-31

5.  Reversible posterior leukoencephalopathy induced by carboplatin and etoposide.

Authors:  S A Ryan; P Maceneaney; S P O'Reilly; E J Moylan; D G Power
Journal:  Med Oncol       Date:  2011-03-10       Impact factor: 3.064

6.  Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy.

Authors:  Melek Kandemir; Belgin Küçükkaya; Muzaffer Savaş Tepe; Zehra Betül Yalçıner; Nedret Taflan Salepçi
Journal:  Balkan Med J       Date:  2015-10-01       Impact factor: 2.021

Review 7.  Posterior reversible encephalopathy syndrome: a neurologic phenomenon in cancer patients.

Authors:  Eileen M Le; Monica E Loghin
Journal:  Curr Oncol Rep       Date:  2014-05       Impact factor: 5.075

8.  Oxaliplatin-induced posterior reversible encephalopathy syndrome (PRES).

Authors:  Taimoor Khalid Janjua; Muhammad Hassan; Hira Khan Afridi; Naila Anjum Zahid
Journal:  BMJ Case Rep       Date:  2017-10-04

9.  Status epilepticus associated with platinum chemotherapy in a patient with cervical cancer: a case report.

Authors:  Laura L Holman; Yulan Ren; Shannon N Westin
Journal:  BMC Cancer       Date:  2015-10-17       Impact factor: 4.430

10.  Atypical reversible leucoencephalopathy syndrome after bevacizumab/folfox regimen for metastatic colon cancer.

Authors:  Narimane Salmi; Ibrahim Elghissassi; Khadija Bellahammou; Asmaa Lakhdissi; Hind Mrabti; Hassan Errihani
Journal:  Case Rep Oncol Med       Date:  2014-10-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.